Cover Image
市場調查報告書

全球思覺失調症治療藥市場

Global Schizophrenia Therapeutics Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 319675
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
全球思覺失調症治療藥市場 Global Schizophrenia Therapeutics Market 2014-2018
出版日期: 2014年11月19日 內容資訊: 英文 102 Pages
簡介

思覺失調症,是阻礙腦的正常功能,嚴重影響患者的生活品質的慢性腦功能障礙。思覺失調症的正確病因還不知道。全球思覺失調症治療藥市場,預計2013年∼2018年以2.82%的年複合成長率增加。

本報告提供全球思覺失調症治療藥市場相關調查分析、市場規模與成長率、市場趨勢、推動市場要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 美國的思覺失調症治療藥市場
    • 市場規模與預測
  • 波特的五力分析

第7章 開發平台概要

第8章 發病率和患者數

美國

第9章 思覺失調症的類型

第10章 思覺失調症的階段

第11章 市場區隔:各藥物分類

第12章 地區區隔

  • 南北美洲的思覺失調症治療藥市場
    • 市場規模與預測
  • 亞太地區的思覺失調症治療藥市場
    • 市場規模與預測
  • 歐洲、中東、非洲地區的思覺失調症治療藥市場
    • 市場規模與預測

第13章 購買標準

第14章 推動市場成長要素

第15章 推動因素與其影響

第16章 市場課題

第17章 推動因素與課題的影響

第18章 市場趨勢

第19章 趨勢與其影響

第20章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第21章 主要供應商分析

  • Astra Zeneca
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Johnson & Johnson
  • 大塚製藥
  • Pfizer Inc.
  • 住友大日本製藥

第22章 相關報告

圖表

目錄
Product Code: IRTNTR4716

About Schizophrenia

Schizophrenia is a chronic brain disorder that severely affects the quality of life of a patient by disturbing the normal functioning of the brain. Psychotic symptoms and a diminished range of expression of emotions are the characteristics of schizophrenia. The exact etiology of schizophrenia is still not known. In men, it appears in the late teens or early 20s, and in women in the late 20s or early 30s. However, most of the symptoms of this disorder can be managed with medication and psychological help.

TechNavio's analysts forecast the Global Schizophrenia Therapeutics market to grow at a CAGR of 2.82 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Schizophrenia Therapeutics market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of schizophrenia that are available in the market. The Global Schizophrenia Therapeutics market can be segmented into two: First-generation Antipsychotics and Second-generation Antipsychotics.

TechNavio's report, the Global Schizophrenia Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Schizophrenia Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lily
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Johnson & Johnson
  • Otsuka Pharmaceuticals
  • Pfizer
  • Sumitomo Dainippon Pharma

Other Prominent Vendors

  • Abbott Laboratories
  • Acadia Pharmaceuticals
  • Alkermes
  • Astellas Pharma
  • Chugai Pharmaceutical
  • Glaxo Smith Kline
  • Merck
  • Mitsubishi Tanabe Pharma
  • Novartis
  • Takeda Pharmaceutical

Market Driver

  • Increase in Aging Population
  • For a full, detailed list, view our report

Market Challenge

  • Increase in Generic Competition
  • For a full, detailed list, view our report

Market Trend

  • Rising Awareness of Schizophrenia
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Schizophrenia Therapeutics Market in the US
    • 06.3.1. Market Size and Forecast
  • 06.4. Five Forces Analysis

07. Pipeline Snapshot

08. Rate of Incidence and Prevalence

    • 08.1.1. US

09. Types of Schizophrenia

10. Phases of Schizophrenia

11. Market Segmentation by Drug Class

12. Geographical Segmentation

  • 12.1. Schizophrenia Therapeutics Market in Americas
    • 12.1.1. Market Size and Forecast
  • 12.2. Schizophrenia Therapeutics Market in the APAC Region
    • 12.2.1. Market Size and Forecast
  • 12.3. Schizophrenia Therapeutics Market in the EMEA Region
    • 12.3.1. Market Size and Forecast

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2013
  • 20.3. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. AstraZeneca
    • 21.1.1. Key Facts
    • 21.1.2. Business Description
    • 21.1.3. Business Segmentation
    • 21.1.4. Business Strategy
    • 21.1.5. Revenue by Business Segmentation
    • 21.1.6. Revenue Comparison 2011-2013
    • 21.1.7. Sales Revenue by Geographical Segmentation
    • 21.1.8. Key Developments
    • 21.1.9. SWOT Analysis
  • 21.2. Bristol-Myers Squibb Co.
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Product Segmentation
    • 21.2.4. Sales by Geography
    • 21.2.5. Business Strategy
    • 21.2.6. Key Information
    • 21.2.7. SWOT Analysis
  • 21.3. Eli Lilly and Co.
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue 2013
    • 21.3.4. Business Segmentation by Revenue 2012 and 2013
    • 21.3.5. Sales by Geography
    • 21.3.6. Business Strategy
    • 21.3.7. Key Developments
    • 21.3.8. SWOT Analysis
  • 21.4. F. Hoffmann-La Roche
    • 21.4.1. Key Facts
    • 21.4.2. Business Overview
    • 21.4.3. Business Segmentation
    • 21.4.4. Business Segmentation by Revenue 2012 and 2013
    • 21.4.5. Geographical Segmentation by Revenue
    • 21.4.6. Business Strategy
    • 21.4.7. Key Information
    • 21.4.8. SWOT Analysis
  • 21.5. H. Lundbeck
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Product Segmentation by Revenue 2013
    • 21.5.4. Product Segmentation by Revenue 2012 and 2013
    • 21.5.5. Geographical Segmentation by Revenue 2013
    • 21.5.6. Business Strategy
    • 21.5.7. Recent Developments
    • 21.5.8. SWOT Analysis
  • 21.6. Johnson & Johnson
    • 21.6.1. Key Facts
    • 21.6.2. Business Overview
    • 21.6.3. Business Segmentation by Revenue 2013
    • 21.6.4. Business Segmentation by Revenue 2012 and 2013
    • 21.6.5. Geographical Segmentation by Revenue 2013
    • 21.6.6. Business Strategy
    • 21.6.7. Recent Developments
    • 21.6.8. SWOT Analysis
  • 21.7. Otsuka Pharmaceuticals
    • 21.7.1. Key Facts
    • 21.7.2. Business Overview
    • 21.7.3. Business Segmentation by Revenue 2014
    • 21.7.4. Business Segmentation by Revenue 2013 and 2014
    • 21.7.5. Geographical Segmentation by Revenue 2014
    • 21.7.6. Business Strategy
    • 21.7.7. Recent Developments
    • 21.7.8. SWOT Analysis
  • 21.8. Pfizer Inc.
    • 21.8.1. Key Facts
    • 21.8.2. Business Description
    • 21.8.3. Business Segmentation
    • 21.8.4. Revenue by Business Segmentation
    • 21.8.5. Revenue Comparison 2012 and 2013
    • 21.8.6. Sales by Geography
    • 21.8.7. Business Strategy
    • 21.8.8. Key Developments
    • 21.8.9. SWOT Analysis
  • 21.9. Sumitomo Dainippon Pharma
    • 21.9.1. Key Facts
    • 21.9.2. Business Overview
    • 21.9.3. Product Segmentation
    • 21.9.4. Products Segmentation by Revenue 2013 and 2014
    • 21.9.5. Business Strategy
    • 21.9.6. Recent Developments
    • 21.9.7. SWOT Analysis

22. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Schizophrenia Therapeutics Market 2013-2018 (US$ billion)
  • Exhibit 3: Schizophrenia Therapeutics Market in the US
  • Exhibit 4: Types of Schizophrenia
  • Exhibit 5: Phases of Schizophrenia
  • Exhibit 6: Global Schizophrenia Therapeutics Market Segmentation by Drug Class
  • Exhibit 7: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013
  • Exhibit 8: Schizophrenia Therapeutics Market in America 2013-2018 (US$ billion)
  • Exhibit 9: Schizophrenia Therapeutics Market in the APAC Region 2013-2018 (US$ billion)
  • Exhibit 10: Schizophrenia Therapeutics Market in the EMEA Region 2013-2018 (US$ billion)
  • Exhibit 11: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013-2018 (US$ billion)
  • Exhibit 12: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013-2018 (in percent)
  • Exhibit 13: Johnson & Johnson Sales by Therapeutic Area (Pharmaceuticals) 2013
  • Exhibit 14: AstraZeneca: Business Segmentation
  • Exhibit 15: AstraZeneca: Revenue by Business Segmentation 2013
  • Exhibit 16: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
  • Exhibit 17: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 18: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
  • Exhibit 19: Bristol-Myers Squibb Co.: Sales by Geography 2013
  • Exhibit 20: Eli Lilly and Co.: Business Segmentation by Revenue 2013
  • Exhibit 21: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 22: Eli Lilly and Co.: Sales by Geography 2013
  • Exhibit 23: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 24: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 25: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
  • Exhibit 26: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
  • Exhibit 27: H. Lundbeck: Business Segmentation by Revenue 2013
  • Exhibit 28: H. Lundbeck: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 29: H. Lundbeck: Geographical Segmentation by Revenue 2013
  • Exhibit 30: Johnson & Johnson: Business Segmentation by Revenue 2013
  • Exhibit 31: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 32: Johnson & Johnson: Geographical Segmentation by Revenue 2013
  • Exhibit 33: Otsuka Pharmaceutical: Business Segmentation by Revenue 2014
  • Exhibit 34: Otsuka Pharmaceutical: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 35: Otsuka Pharmaceutical: Geographical Segmentation by Revenue 2014
  • Exhibit 36: Pfizer Inc.: Business Segmentation
  • Exhibit 37: Pfizer Inc.: Revenue by Business Segmentation 2013
  • Exhibit 38: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
  • Exhibit 39: Pfizer Inc.: Revenue by Geography 2013
  • Exhibit 40: Sumitomo Dainippon Pharma: Product Segmentation 2014
  • Exhibit 41: Sumitomo Dainippon Pharma: Product Segmentation by Revenue 2013 and 2014
Back to Top